Zydol XL 150mg Tabs
Last Updated on eMC 11-May-2017 View document | Grunenthal Ltd Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 11-May-2017 and displayed until Current
Reasons for adding or updating:
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Date of revision of text on the SPC: 05-May-2017
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 5.1: Pharmacodynamic properties
Information on paediatric population included
Section 5.2: Pharmacokinetic properties
Information on paediatric population included
Section 10: Date of revision of the text
05 May 2017
Updated on 24-Jul-2014 and displayed until 11-May-2017
Reasons for adding or updating:
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 10 - Date of revision of the text
Date of revision of text on the SPC: 11-Jul-2014
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 4.7 - addition of drug driving warning in line with MHRA directionsUpdated on 28-Feb-2014 and displayed until 24-Jul-2014
Reasons for adding or updating:
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Date of revision of text on the SPC: 14-Feb-2014
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 4.8:hypoglycaemia added as adverse event of unknown frequency
Updated on 04-Jan-2013 and displayed until 28-Feb-2014
Reasons for adding or updating:
- Change to section 4.2 - Posology and method of administration
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Date of revision of text on the SPC: 30-Nov-2012
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 4.2: Dosing in Geriatric patients and patients with renal insufficiency/hepatic impairment has been revised to provide specific details.
Section 4.5: Interaction by concomitant use of tramadol and serotonergic drugs has been revised to provide further clarity.
Updated on 31-Jan-2011 and displayed until 04-Jan-2013
Reasons for adding or updating:
- Change to section 1 -Name of the Medicinal product
Date of revision of text on the SPC: 08-Oct-2010
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 1 - ‘ZYDOL XL 150 mg tablets’ updated to ‘ZYDOL XL 150 mg prolonged release tablets.’
Updated on 14-Jun-2006 and displayed until 31-Jan-2011
Reasons for adding or updating:
- No reasons supplied
Date of revision of text on the SPC: 01-Dec-2005
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Updated on 26-Jul-2005 and displayed until 14-Jun-2006
Reasons for adding or updating:
- New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Grunenthal Ltd
Units 1 and 2 Stokenchurch Business Park, Ibstone Road, Stokenchurch, Buckinghamshire, HP14 3FE, UK
+44 (0)870 351 8960
+44 (0)1494 486298
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue